TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6712031
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose recombinant alpha-2 interferon (50 X 10(6) U/m2 body surface area, intravenously)
Study: 6712031
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose recombinant alpha-2 interferon (1 X 10(6) U/m2, subcutaneously)
Study: 6712031
Drug: Both high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high and low doses of recombinant alpha-2 interferon
Study: 31741230
Drug: Biomarker-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided therapy
Study: 24476536
Drug: Intrauterine injection
Normalized name: ETHIODIZED OIL 480 mg in 1 mL INTRAUTERINE INJECTION [LIPIODOL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine injection of 500 IU of human chorionic gonadotropin (hCG) before embryo transfer
Study: 24476536
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hCG injection)
Study: 20665209
Drug: Oxycodone (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (5, 10, and 20 mg/10 ml)
Study: 20665209
Drug: Hydrocodone (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone (5, 10, and 20 mg/10 ml)
Study: 20665209
Drug: Morphine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5, 10, and 20 mg/10 ml)
Study: 9704792
Drug: Antiphospholipid antibody
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibody
Study: 8580691
Drug: More concentrated
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More concentrated PAP (10 ml = 15 grams of Astragalus)
Study: 8580691
Drug: Less concentrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less concentrated PAP (10 ml = 5 grams of Astragalus)
Study: 31192359
Drug: Supervised machine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised machine learning approach using PBP sequences and MIC values to predict antimicrobial susceptibility to beta-lactam antibiotics.
Study: 28251282
Drug: S-1 alternate-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 alternate-day treatment (twice daily on alternate days from days 1 through 42 of a 42-day cycle)
Study: 28251282
Drug: S-1 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 daily treatment (twice daily on days 1 through 28 of a 42-day cycle)
Study: 28251282
Drug: S-1 alternate-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 alternate-day treatment
Study: 28251282
Drug: S-1 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 daily treatment
Study: 18710817
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection in trapezius muscle
Study: 18710817
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection in trapezius muscle (control)
Study: 16752180
Drug: [U‐(13)C]glucose and
Approvals — FDA: no, EMA: no, PMDA: no
Description: [U‐(13)C]glucose and [3‐(14)C]lactate infusion during a 24‐h fast
Study: 15177970
Drug: One 600‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 600‐mg tablet (group 1A, 13 patients sampled < 2 hours after administration)
Study: 15177970
Drug: One 600‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 600‐mg tablet (group 1B, 9 patients sampled > 2 hours after administration)
Study: 15177970
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 600 mg given 12 hours apart (group 2, 7 patients)
Study: 3112262
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.1 mg/kg)
Study: 24225450
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg daidzein (DAI40)
Study: 24225450
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg daidzein (DAI80)
Study: 20937093
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (25,000 U) administered 4 or 6 hourly depending on patient height
Study: 20937093
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered 4 or 6 hourly depending on patient height
Study: 18763689
Drug: Oral‐B P40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B P40 manual toothbrush (MTB)
Study: 16105056
Drug: Cinacalcet (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30 to 180 mg once daily)
Study: 31478731
Drug: Multi-drug resistance
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug resistance
Study: 26115954
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for depression, 8 weeks
Study: 22916864
Drug: Titanium-polyethylene (TI)
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium-polyethylene (TI) implant
Study: 22916864
Drug: Pyrocarbon (PY)
Normalized name: PARAFFIN HYDROCARBONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrocarbon (PY) implant
Study: 20581660
Drug: Dexamethasone (HD-DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (HD-DXM) at single daily doses of 40 mg for 4 consecutive days
Study: 17295794
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (daily for the first 6 months of life)
Study: 17295794
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for the first 6 months of life)
Study: 2036815
Drug: Aerosol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol therapy
Study: 2036815
Drug: Humidity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidity therapy
Study: 7094200
Drug: Chemotherapy (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (with or without radiotherapy) plus MER/BCG (RCM)
Study: 7094200
Drug: Chemotherapy either
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy either alone or in combination with radiotherapy (RC)
Study: 26947543
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (IVTXA)
Study: 26947543
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (TTXA)
Study: 14711141
Drug: Topical 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5‐FU
Study: 14711141
Drug: PDT treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT treatments (both types)
Study: 11281438
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg tid + Omeprazole 20 mg bd
Study: 11281438
Drug: Amoxycillin 750
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 750 mg tds + Omeprazole 20 mg bd
Study: 11281438
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg tid + Omeprazole 20 mg bd
Study: 9426077
Drug: Mannitol inhalation
Normalized name: mannitol inhalation kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol inhalation (267 mg and 400 mg)
Study: 9309990
Drug: Mannitol inhalation
Normalized name: mannitol inhalation kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol inhalation
Study: 3941767
Drug: Primidone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primidone (50 to 1,000 mg/d)
Study: 3941767
Drug: Primidone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primidone (250 mg single oral dose)
Study: 23887656
Drug: Aliskiren add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren add-on therapy
Study: 23887656
Drug: Benazepril add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril add-on therapy
Study: 17551539
Drug: Nicotine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2 mg via polacrilex gums)
Study: 8881668
Drug: Higher-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose regimen based on minimal phototoxic dose (MPD)
Study: 8881668
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose regimen based on skin type
Study: 1909584
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg nocte
Study: 25295737
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + taxane-based chemotherapy
Study: 20880343
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 50/50 (LM50/50)
Study: 20880343
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus ≤3 mealtime lispro (G+L)
Study: 18035140
Drug: Insulin (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.025 U/kg/hr) on days 1 to 7 with 20% dextrose to maintain normoglycemia
Study: 12753317
Drug: Raloxifene hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene hydrochloride, 60 mg/day
Study: 11421376
Drug: Albendazole 20
Normalized name: albendazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 20 mg/kg with cimetidine 10 mg/kg twice daily
Study: 11421376
Drug: Albendazole 5
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 5 mg/kg
Study: 8872129
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg IK-HIR02 (IV)
Study: 8872129
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg IK-HIR02 (IV)
Study: 8872129
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg IK-HIR02 (IV)
Study: 8872129
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg IK-HIR02 (SC)
Study: 8872129
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg IK-HIR02 (SC)
Study: 8872129
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg IK-HIR02 (SC)
Study: 8872129
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg IK-HIR02 (SC, b.i.d.)
Study: 8872129
Drug: Hirudin (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (0.7 micrograms/ml) as anticoagulant
Study: 1900575
Drug: Thyroxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine (100 micrograms) and Methimazole (10 mg)
Study: 1900575
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and Methimazole (10 mg)
Study: 6823860
Drug: Clonidine (centrally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (centrally acting agent)
Study: 29746446
Drug: Corner Pocket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corner Pocket technique (20 mL local anesthetic injected primarily in the corner pocket)
Study: 29746446
Drug: Neural Cluster
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural Cluster technique (20 mL local anesthetic injected primarily inside the neural cluster)
Study: 26143238
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression with concentrated bone marrow injection (Group A)
Study: 26143238
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression without bone marrow injection (Group B)
Study: 20452184
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules containing Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium lactis, and Streptococcus thermophiles for 6 months
Study: 20452184
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules for patients with baseline ammonia levels > 50 mmol/L
Study: 17000789
Drug: Dopamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (2 mcg x kg(‐1) x min(‐1))
Study: 1614100
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (Voltaren Ophtha)
Study: 27793396
Drug: Alirocumab 75/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75/150 mg every 2 weeks (Q2W)
Study: 18699977
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI) therapy
Study: 20464583
Drug: Frovatriptan (F)
DrugBank: Frovatriptan (DB00998)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frovatriptan (F) 2.5 mg
Study: 22644174
Drug: Comparators (Rizatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparators (Rizatriptan (R) 10 mg, Zolmitriptan (Z) 2.5 mg, Almotriptan (A) 12.5 mg)
Study: 10597985
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (single high dose every 4 months)
Study: 11144995
Drug: ARA (adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA (adenosine receptor agonist)
Study: 11144995
Drug: Hypothetical antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hypothetical antagonist
Study: 7602348
Drug: Intense therapy
Normalized name: AVOBENZONE 30 g in 1000 g / OCTINOXATE 75 g in 1000 g / PETROLATUM 402 g in 1000 g TOPICAL OINTMENT [Intense Therapy Lip Balm Asian Pear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense therapy (cyclophosphamide 1,000 mg/m2 and cisplatin 100 mg/m2 intravenously every 3 weeks for four courses)
Study: 7602348
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (cyclophosphamide 500 mg/m2 and cisplatin 50 mg/m2 intravenously every 3 weeks for eight courses)
Study: 7602348
Drug: Intense therapy
Normalized name: AVOBENZONE 30 g in 1000 g / OCTINOXATE 75 g in 1000 g / PETROLATUM 402 g in 1000 g TOPICAL OINTMENT [Intense Therapy Lip Balm Asian Pear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense therapy
Study: 2186769
Drug: Warfarin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (1 mg daily minidose)
Study: 28780236
Drug: Tenecteplase 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase 0.4 mg/kg (max 40 mg)
Study: 28780236
Drug: Alteplase 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 0.9 mg/kg (max 90 mg)
Study: 19841760
Drug: G‐Bond (GC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Bond (GC)
Study: 17376791
Drug: Tenofovir 300
Normalized name: tenofovir 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir 300 mg once daily
Study: 10378549
Drug: Empiric anti-PCP
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric anti-PCP therapy
Study: 3959798
Drug: Preoperative gamma-therapy
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative gamma-therapy at a dose of 19.5 Gy
Study: 3959798
Drug: Preoperative gamma-therapy
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative gamma-therapy at a dose of 30 Gy
Study: 3959798
Drug: Preoperative gamma-therapy
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative gamma-therapy at a dose of 40 Gy
Study: 31734084
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray plus an oral antidepressant
Study: 31734084
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral antidepressant
Study: 28991048
Drug: Hydrocortisone 300
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 300 mg group (100 mg initial bolus followed by continuous infusion of 300 mg daily for 5 days)
Study: 28991048
Drug: Hydrocortisone 200
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 200 mg group (50 mg intravenous bolus every 6 h during 7 days)
Study: 28991048
Drug: Nonresponders (CST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders (CST response of 9 μg/dL or less)
Study: 25223164
Drug: Chewing gauze
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewing gauze soaked with 20 ml of 2% lidocaine
Study: 10023125
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human nerve growth factor (rhNGF) administered at doses of 0.1 or 0.3 microg/kg subcutaneously 3 days a week for 6 months.
Study: 10023125
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human nerve growth factor (rhNGF) administered at doses up to 1.0 microg/kg intravenously or subcutaneously for up to 12 doses in phase I studies.
Study: 8678284
Drug: Piritramide (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritramide (bolus 1.5 mg)
Study: 1987875
Drug: Bile acid
Normalized name: Bile acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile acid therapy compliance
Study: 6857584
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg four times daily)
Study: 25601896
Drug: Intramuscular single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular single dose of 300,000 IU vitamin D3
Study: 17953631
Drug: Antioxidant pool
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant pool (AP) supplementation for 2 months before and 6 months during NB‐UVB treatment
Study: 12037659
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml tomato juice with 300 mg HCA
Study: 12037659
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml tomato juice (placebo)
Study: 12555375
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine associated with enalapril or hydrochlorothiazide)
Study: 1800166
Drug: Topical 2-(2-Hydroxy-4-methylphenyl)
Normalized name: benzocaine 0.2 MG/MG [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2-(2-Hydroxy-4-methylphenyl) Aminothiazole Hydrochloride 0.1% (CBS 113A)
Study: 6391903
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (30 ml)
Study: 6391903
Drug: Linseed oil
Normalized name: linseed oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linseed oil (30 ml)
Study: 29526850
Drug: Transcranial Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Direct Current Stimulation therapy
Study: 29526850
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Transcranial Direct Current Stimulation + Positive psychotherapy)
Study: 26953280
Drug: U‐300 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U‐300 insulin glargine
Study: 26953280
Drug: U‐100 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U‐100 insulin glargine
Study: 25070099
Drug: 7-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day standard triple therapy (pantoprazole, clarithromycin, amoxicillin for 7 days)
Study: 25070099
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, clarithromycin, and metronidazole for a further 5 days)
Study: 25070099
Drug: 7-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day concomitant therapy (pantoprazole, clarithromycin, amoxicillin, and metronidazole for 7 days)
Study: 16029670
Drug: 4% hydroquinone/0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroquinone/0.3% retinol cream
Study: 11735710
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin emollient cream
Study: 10439767
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion (0.5 microgram.kg‐1.min‐1 i.v.)
Study: 2121150
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (30 g in red port and wine) consumed during a standard dinner
Study: 18782641
Drug: Exenatide twice
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice daily
Study: 26545669
Drug: Ganoderma lucidum
Normalized name: GANODERMA LUCIDUM STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganoderma lucidum (6 g per day for 6 weeks)
Study: 26545669
Drug: Ceratonia siliqua
Normalized name: CERATONIA SILIQUA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceratonia siliqua (6 g per day for 6 weeks)
Study: 15983798
Drug: Clonidine 0.2
Normalized name: CLONIDINE 0.2MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2 mg
Study: 9108861
Drug: Tricomponent acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricomponent acellular pertussis-diphtheria-tetanus vaccine (fourth dose)
Study: 3076140
Drug: Pinacidil 12.5
Normalized name: pinacidil 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 12.5 mg bid with Hydrochlorothiazide 12.5 mg bid
Study: 3076140
Drug: Pinacidil 12.5
Normalized name: pinacidil 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 12.5 mg bid
Study: 3076140
Drug: Pinacidil 25
Normalized name: pinacidil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 25 mg bid
Study: 3076140
Drug: Pinacidil 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 37.5 mg bid
Study: 3076140
Drug: Pinacidil (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (low doses 12.5-25 mg bid)
Study: 31229307
Drug: Haloperidol (antipsychotic)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (antipsychotic)
Study: 23669822
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil (3.1 ± 1.9 mg bid)